Valuation: Univo Pharmaceuticals Ltd

Market Cap 56.8M 0 50.47M 47.1M 42.93M 80.97M 5.46B 81.73M 570M 221M 2.79B 213M 209M 8.96B P/E 2019 *
-
P/E 2020 -
Enterprise Value 60.92M 0 54.13M 50.52M 46.05M 86.85M 5.86B 87.66M 611M 237M 2.99B 229M 224M 9.61B EV / Sales 2019
35,543,010x
EV / Sales 2020 2,352,105x
Free-Float
63.83%
Yield 2019 *
-
Yield 2020 -
Current month+900.00%
Current year+900.00%
5 years 90,000
Extreme 90000
2,792,000
10 years 90,000
Extreme 90000
7,488,000
Manager TitleAgeSince
Chief Executive Officer 50 2018-09-05
Investor Relations Contact - -
Comptroller/Controller/Auditor 44 2021-12-31
Director TitleAgeSince
Chairman 66 2019-07-14
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00% - - 918K
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+20.19%+81.44% 57.39B
+0.89%-0.63%+2.17%+36.19% 47.64B
+0.36%+0.81%+342.39%+742.40% 44.29B
-0.96%-4.50%+24.96%+35.38% 42.5B
-0.20%-0.77%+4.13%+105.50% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.33%+22.72% 28.53B
+0.05%-1.64%-8.14%-11.37% 24.34B
Average -0.20%-0.53%+52.63%+128.54% 39.05B
Weighted average by Cap. +0.12%-0.84%+56.96%+138.26%

Financials

2019 2020
Net sales 0.82 0 0.73 0.68 0.62 1.17 79.21 1.19 8.27 3.2 40.49 3.09 3.03 129.96 33.68 0 29.92 27.93 25.46 48.01 3.24K 48.46 338 130.97 1.66K 126.45 123.71 5.31K
Net income -11.79M -0 -10.47M -9.78M -8.91M -16.81M -1.13B -16.96M -118M -45.85M -579M -44.26M -43.3M -1.86B 183K 0 163K 152K 138K 261K 17.59M 263K 1.84M 712K 8.99M 687K 672K 28.86M
Net Debt -22.82M -0 -20.28M -18.92M -17.25M -32.53M -2.19B -32.83M -229M -88.74M -1.12B -85.68M -83.82M -3.6B 4.12M 0 3.66M 3.42M 3.11M 5.87M 396M 5.93M 41.35M 16.02M 202M 15.47M 15.13M 650M
Logo Univo Pharmaceuticals Ltd
Univo Pharmaceuticals Ltd is an Israel-based biotech company. The Company is focused on developing drugs for the treatment of central nervous system (CNS) conditions. Its area of interest is in developing medicine for degenerative and age-related disorders. The Company’s product portfolio includes three clinical Phase II drug-candidates: THR-18 for thrombolysis, to restore blood flow to the brain, heart or lungs, which completed clinical Phase I and Phase II study in acute stroke patients receiving tPA; DP-VPA for the treatment of epilepsy, migraine and manic depression, which has completed a Phase II study in patients with complex partial epilepsy, and DP-b99, which contains calcium, zinc and copper ions and is used for the protection of cells under stress in acute pancreatitis. The Firm’s two technology platforms Membrane Activated Chelator and Regulated Activation of Prodrug use lipid moieties conjugated onto actives such as metal ion chelators or drugs for site specific activation.
Employees
-
Date Price Change
26-10-01 ILA 930,000.00 0.00%
26-09-30 ILA 930,000.00 0.00%
26-09-29 ILA 930,000.00 0.00%
26-09-28 ILA 930,000.00 0.00%
26-09-24 ILA 930,000.00 0.00%
  1. Stock Market
  2. Stocks
  3. UNVO-M Stock